AnaptysBio, Inc. (ANAB) Investor Relations Documents

AnaptysBio, Inc. (ANAB) investor relations documents from the company's IR site: 3 presentations, 16 press releases; latest deck 2026-05-12. Read in-app with summaries. First-party data.

AnaptysBio Corporate Presentation May 2026: AnaptysBio is a virtual biotech managing royalty streams from GSK’s Jemperli, which generated $313 million in Q1 2026 sales.

Investor relations documents — source: company IR site

Published	Type	Document
2026-05-12	Presentation	AnaptysBio Corporate Presentation May 2026
2026-05-12	Press release	Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-11	Press release	Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
2026-05-04	Press release	Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
2026-04-24	Press release	Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
2026-04-20	Press release	Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collabo
2026-03-27	Press release	First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
2026-03-27	Press release	Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
2026-03-27	Press release	Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
2026-03-03	Press release	Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
2026-02-05	Press release	Anaptys Announces Participation at Upcoming Investor Conferences
2026-01-08	Press release	Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro,
2026-01-06	Press release	Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
	Press release	Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
2025-10-14	Presentation	Presentation
2025-09-29	Presentation	PRESENTATION
	Press release	Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
	Press release	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
	Press release	GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointes

ANAB overview · ANAB earnings · ANAB financials · ANAB KPIs · ANAB documents · ANAB ownership · ANAB peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.